way from the decision tree model. Methods: From Jan 2017 to Jan 2018, we extracted patients with asthma using the conventional operational definition at the catholic University of Korea. Total 4235 patients were extracted. We excluded patients younger than 19 years of age and patients who didn't visit pulmonology and allergy clinic. Using the prescribed drugs to define asthma, we developed a tree-based decision model in the previous study and a Logistic Regression model in this study. Results: Total 353 patients were enrolled in this study. One hundred fifty nine (43.3%) patients were nor eligible for asthma. Of these, 85 (24.1%) patients were chronic obstructive pulmonary disease, followed by bronchitis (n = 21, 5.9%), bronchiolitis obliterans (n = 20, 5.7%), solid malignancy (n = 11, 3.1%), bronchiectasis (n = 10, 2.8%) and others (n = 12, 3.4%). By a Logistic Regression model, Overall accuracy was 87.4%, sensitivity and specificity were 88.9% and 84.8%. Conclusions: The conventional operational definition of asthma has limitation to extract true asthma patients in real world. Therefore, it is necessary to establish an accurate standardized operational definition of asthma. Meanwhile, this study found some drugs that significantly affect the prediction. Also, we could see form this study a slight improvement in Accuracy and Sensitivity compared to the tree-based decision model. In general, however, all of these two models may be considered to have adequate explanatory power, given that there is no significant difference. (Grant number:HI18C0522)
polynomial (FP) models using survivalNMA package in R (v3.6.2) and parameters were estimated accordingly. A deviance information criterion (DIC) was used to compare the goodness-of-fit. Results: Among the parametric and FP models, loglogistic showed the best fit (DIC=431.65; 248.18), followed by FP1 and Weibull for both PFS and OS outcomes. The predicted survival of lanreotide LAR, octreotide LAR, and placebo was 44%, 40% and 6% in terms of PFS at 5 years, and 54%, 57% and 54% in terms of OS at 10 years. Lanreotide LAR showed highest PFS, followed by octreotide LAR and Placebo. Regarding OS, octreotide LAR showed the highest survival, while lanreotide LAR and placebo showed near-identical survival prospects. The findings were not sensitive to different distributions, although the survival probabilities varied substantially. The ordering of treatments was also consistent across distributions. Conclusions: Octreotide LAR and lanreotide LAR significantly delayed the time to progression compared to placebo. The results of our multi-dimensional evidence synthesis approach are consistent with previously published HR based metaanalyses. The use of this approach may be more informative for any subsequent costeffectiveness modelling over constant HRs.
year early-listing model was estimated at 0.68% of the total anticancer drug sales in 2017. Conclusions: Prices of anticancer drugs in Korea were similar to those among A7 countries based on the lowest price of anticancer drugs. It is recommended that a new 'pre-listing and post-evaluation' model, which references prices from A7 countries, be implemented to improve patient access to novel anticancer drugs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.